GCG and pancreatic neoplasm: There have been concerns regarding the safety of GLP-1 agonists since Raufman et al. reported in the early 90 s that GLP-1 interacted with exendin receptors on dispersed acini from guinea pig pancreas22,23, and these concerns were increased with the results from the LEADER trial showing a numerically greater, although statistically not significant, number of cases of pancreatic cancer in the liraglutide arm compared to the placebo20.